Dynamics of tumor hypoxia measured with bioreductive hypoxic cell markers. by Ljungkvist, A. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/52207
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
BioOne sees sustainable scholarly publishing as an inherently collaborative enterprise connecting authors, nonprofit publishers, academic institutions, research
libraries, and research funders in the common goal of maximizing access to critical research.
Dynamics of Tumor Hypoxia Measured with Bioreductive Hypoxic Cell Markers
Author(s) :Anna S. E. Ljungkvist, Johan Bussink, Johannes H. A M. Kaanders, and Albert J. van der
Kogel
Source: Radiation Research, 167(2):127-145. 2007.
Published By: Radiation Research Society
DOI: http://dx.doi.org/10.1667/RR0719.1
URL: http://www.bioone.org/doi/full/10.1667/RR0719.1
BioOne (www.bioone.org) is a nonprofit, online aggregation of core research in the biological, ecological, and
environmental sciences. BioOne provides a sustainable online platform for over 170 journals and books published
by nonprofit societies, associations, museums, institutions, and presses.
Your use of this PDF, the BioOne Web site, and all posted and associated content indicates your acceptance of
BioOne’s Terms of Use, available at www.bioone.org/page/terms_of_use.
Usage of BioOne content is strictly limited to personal, educational, and non-commercial use. Commercial inquiries
or rights and permissions requests should be directed to the individual publisher as copyright holder.
127
RADIATION RESEARCH 167, 127–145 (2007)
0033-7587/07 $15.00
 2007 by Radiation Research Society.
All rights of reproduction in any form reserved.
REVIEW
Dynamics of Tumor Hypoxia Measured with Bioreductive Hypoxic
Cell Markers
Anna S. E. Ljungkvist,1 Johan Bussink, Johannes H. A. M. Kaanders and Albert J. van der Kogel
Department of Radiation Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Ljungkvist, A. S. E., Bussink, J., Kaanders, J. H. A. M. and
van der Kogel, A. J. Dynamics of Tumor Hypoxia Measured
with Bioreductive Hypoxic Cell Markers. Radiat. Res. 167,
127–145 (2007).
Hypoxic cells are common in tumors and contribute to ma-
lignant progression, distant metastasis and resistance to ra-
diotherapy. It is well known that tumors are heterogeneous
with respect to the levels and duration of hypoxia. Several
strategies, including high-oxygen-content gas breathing, ra-
diosensitizers and hypoxic cytotoxins, have been developed to
overcome hypoxia-mediated radioresistance. However, with
these strategies, an increased tumor control rate is often ac-
companied by more severe side effects. Consequently, devel-
opment of assays for prediction of tumor response and early
monitoring of treatment responses could reduce both over-
and undertreatment, thereby avoiding unnecessary side ef-
fects. The purpose of this review is to discuss different assays
for measurement of hypoxia that can be used to detect chang-
es in oxygen tension. The main focus is on exogenous biore-
ductive hypoxia markers (2-nitroimidazoles) such as pimoni-
dazole, CCI-103F, EF5 and F-misonidazole. These are specif-
ically reduced and bind to macromolecules in viable hypoxic
cells. A number of these bioreductive drugs are approved for
clinical use and can be detected with methods ranging from
noninvasive PET imaging (low resolution) to microscopic im-
aging of tumor sections (high resolution). If the latter are
stained for multiple markers, hypoxia can be analyzed in re-
lation to different microenvironmental parameters such as
vasculature, proliferation and endogenous hypoxia-related
markers, for instance HIF1 and CA-IX. In addition, tem-
poral and spatial changes in hypoxia can be analyzed by con-
secutive injection of two different hypoxia markers. There-
fore, bioreductive exogenous hypoxia markers are promising
as tools for development of predictive assays or as tools for
early treatment monitoring and validation of potential endog-
enous hypoxia markers.  2007 by Radiation Research Society
1 Address for correspondence: Department of Radiation Oncology-874,
Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The
Netherlands; e-mail: A.Ljungkvist@rther.umcn.nl.
CLINICAL RELEVANCE OF HYPOXIA
Clinically relevant levels of hypoxia are detected in
about 50–60% of all solid tumors irrespective of size and
histopathological features (1). Hypoxia is associated with
tumor progression, increased aggressiveness, enhanced
metastatic potential and a poor prognosis due to clonal se-
lection or genomic or proteomic changes (2–6). In addition,
hypoxia affects different anticancer treatments negatively.
More than half a century ago, it was demonstrated that
the effect of radiation is affected by the oxygenation status
of the tissue (7, 8). Over the past decades, evidence has
accumulated showing that hypoxia is one of the major fac-
tors influencing radiotherapy negatively. Pretreatment ox-
ygen tensions (pO2 values) were predictive for local control
and survival after surgery or radiotherapy in head and neck
carcinomas and carcinomas of the uterine cervix (9–12).
Different approaches have been developed to overcome
treatment resistance caused by hypoxia, including the use
of hypoxic cell sensitizers such as misonidazole and ni-
morazole (13), the use of vasoactive drugs such as nicotin-
amide (14), high-oxygen gas breathing under normo- or
hyperbaric conditions (15–18), and hypoxic cytotoxins such
as tirapazamine (19, 20). An analysis of 83 randomized
clinical trials comparing radiotherapy alone and radiother-
apy combined with treatments designed to modify or target
tumor hypoxia showed that both local control and survival
could be improved by reducing or specifically targeting tu-
mor hypoxia (21).
Although oxygenation-modifying treatment protocols
generally increase both local control rate and overall sur-
vival in several patient categories, not all of the patients
treated benefit from these treatment approaches. Dynamic
measurements of hypoxia during oxygenation-modifying
treatments such as carbogen breathing could enable selec-
tion of responding and nonresponding patients. For the non-
responders, a reduction of unnecessary overtreatment
would result in decreased side effects for these patients,
allowing selection of another treatment modality that might
be more appropriate, for example specifically targeting hyp-
oxic cells, such as with tirapazamine.
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The purpose of this review is to give an overview of the
relevance of tumor cell hypoxia and different techniques
for detection and quantification of hypoxia. The main focus
is on exogenous bioreductive hypoxia markers (2-nitroim-
idazoles), which label viable hypoxic cells. These hypoxia
markers can be detected with various techniques, and by
means of consecutive injection of two different hypoxia
markers, temporal and spatial changes in hypoxia can be
detected.
PATHOPHYSIOLOGY OF HYPOXIA
Various aspects of tumor biology, for example hypoxia
and proliferation, are often studied in isolation. However,
the tumor microenvironment comprises a dynamic system
with complex structural and functional interactions. It is
characterized by abnormal and heterogeneously organized
tumor vasculature with reduced functionality (22–26), and
considerable differences have been reported among tumors
of the same localization, histology or differentiation grade.
The intervascular distances are generally longer in tumors
than in normal tissue (27–29), and tumors often have an
imbalance between tumor cell proliferation and cell death.
Consequently, tumor cells frequently outgrow the vascula-
ture, which contributes to the development of tumor cell
hypoxia.
In the 1950s and 1960s, corded tumor structures were
described that consisted of blood vessels surrounded by vi-
able tumor cells followed by necrosis at greater distances
from the vessels. Thomlinson and Gray postulated that the
expected oxygen diffusion distance in tissue would be ap-
proximately 150 m, which was in accordance with the
thickness of the cord of viable tumor cells (22, 30). It was
suggested that the presence of necrosis could be explained
by diffusion-limited starvation, with oxygen being a limit-
ing factor. The presence of this kind of diffusion-limited,
chronic hypoxia has been verified with bioreductive hyp-
oxia markers such as CCI-103F, pimonidazole and EF5.
The labeled tumor cells are generally found at greater dis-
tances from blood vessels, with increasing staining inten-
sities along gradients of decreasing oxygen tensions. The
most intensely stained cells are often located in the peri-
necrotic regions (25, 31–35).
Evidence of heterogeneous and intermittent blood flow
has been obtained by window chamber studies of rat rhab-
domyosarcomas (36). Complete occlusion of blood flow
would result in rapid consumption of the remaining oxygen
in the surrounding tissue. Therefore, it was suggested that
perfusion-limited, acute hypoxia could occur as a conse-
quence of transient changes in tumor blood flow (37). This
was verified in vivo in experimental tumors by the use of
two consecutively injected perfusion markers, Hoechst
33342 and DiOC7 (38). Complete vascular occlusions are
rather uncommon; however, small changes in perfusion rate
involving individual vessels or clusters of vessels frequent-
ly may occur (39–42). These can cause steep longitudinal
gradients of oxygen and nutrients along vessels, resulting
in transient periods of hypoxia (43, 44). The presence of
tumor vessels with plasma flow but low or absent red blood
cell flux indicates that diffusion-limited chronic hypoxia
may also be present in the vicinity of blood vessels (42).
Thus intermittent levels of hypoxia may originate from per-
fusion or diffusion limitations but more likely from a mix-
ture of these (43), while the number of blood vessels in the
tumor stroma does not necessarily reflect the tumor blood
flow. Therefore, low perfusion rates and hypoxia may be
present in tumor tissue despite high densities of (nonfunc-
tional) vessels. Consequently, in many tumors the hypoxic
cell population is heterogeneous with respect to the level
and duration of hypoxia.
DETECTION OF HYPOXIA
The importance of hypoxia for radiation treatment and
as a specific target for anticancer treatments (45) indicates
the need for measurements of clinically relevant hypoxia.
Therefore, assays are needed (1) for prediction of patient
outcome, (2) as a tool to select treatments on an individual
basis, and (3) for evaluation of early treatment response.
To achieve this, further understanding of tumor cell hypoxia
in relation to other clinically relevant parameters is neces-
sary (46). Although several methods exist for detection of
hypoxia, only the Eppendorf electrode (9, 47, 48) and the
bioreductive hypoxic cell markers pimonidazole and EF5
(12, 49) have shown prognostic significance in clinical
studies or have been able to discriminate responders from
nonresponders on a group basis.
The assays that are available for detection of tissue hyp-
oxia can be divided into three major groups: (1) direct mea-
surements of oxygen tension, (2) endogenous cell markers
being expressed under hypoxic conditions, and (3) exoge-
nous nitroimidazole-based assays (5, 50, 51). The relevance
of data obtained with the above-mentioned methods can be
compared to the radiobiological hypoxic fraction obtained
by the comet assay (52, 53) and paired survival curve assay
(54, 55). Direct comparisons among studies using different
assays are complicated due to the fact that the definitions
of hypoxia, the spatial resolutions, and the timing of anal-
yses differ. Most of the available assays provide static in-
formation about the tissue oxygenation status. However,
some methods have been developed to allow measurements
of changes in the oxygenation status over time.
DEFINITIONS OF HYPOXIA
Hypoxia can be described as the oxygen tension at which
the metabolic demand in stroma, endothelial cells and tu-
mor cells exceeds the supply. Oxygen tensions ranging
from near atmospheric levels of 21% O2 (159 mmHg) to
2–8% (15–60 mmHg) are found in normal tissues (56),
making it difficult to define hypoxia as being at or below
a specific pO2 value. Due to differences in experimental
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end points and in detection methods, several definitions of
tumor hypoxia exist in the literature. Therefore, it is im-
portant to clearly define hypoxia in publications. Some of
the most common definitions of tumor hypoxia are outlined
below. The radiobiological hypoxic fraction is based on the
difference in survival between tumors or cells irradiated
under ambient compared to anoxic conditions. In in vitro
studies, the hypoxic conditions for cell cultures are often
defined as parts per million. Direct measurements of the
oxygen tension with electrodes such as Eppendorf and
OxyLite are commonly expressed in mmHg, and tumor
hypoxia is often defined as the fraction of measurements
with a pO2  10, 5 or 2.5 mmHg. In contrast, hypoxia
detected with exogenous bioreductive markers in immu-
nohistochemically stained tumor sections is often expressed
as the fraction of the tumor cells or surface that is labeled
with the hypoxia marker. Therefore, caution has to be taken
when different assays are compared. Throughout this re-
view, hypoxia is generally defined as the proportion of cells
with pO2  10 mmHg corresponding to the oxygen tension
below which a steep increase in reduction and binding of
2-nitroimidazoles is found.
DIRECT MEASUREMENTS OF OXYGEN TENSION
Oxygen Electrodes
Direct real-time measurements of oxygen tension in tis-
sue can be performed with oxygen electrodes such as the
Eppendorf polarographic needle electrode (50, 57, 58)2
and the OxyLite fiber-optic probe (59–61). Despite dif-
ferences in modes of action, measurements with the Ep-
pendorf electrode and OxyLite probe result in compa-
rable pO2 values in the range of 0–30 mmHg (61, 62).
The Eppendorf electrode consumes small amounts of
oxygen and is moved throughout the tissue during mea-
surements providing multiple samplings. The Eppendorf
electrode provided the first clinical evidence that intratu-
moral oxygen tension was predictive of locoregional con-
trol (57) or survival in human cancers (63). Based on po-
larographic pO2 measurements, it was possible to separate
responders from nonresponders in several clinical trials (9,
47, 48). Therefore, many investigators have considered Ep-
pendorf measurements as a ‘‘gold standard’’ of hypoxia
in human tumors (46, 50).
The OxyLite probe does not consume oxygen during
measurements and can be left at one position for a longer
period (61, 64). OxyLite can detect temporal fluctuations
in pO2 of intrinsic origin (60) or changes induced by oxy-
gen-modifying treatments such as carbogen breathing (59,
65) or hydralazine (66). In addition, the fiber-optic Oxy-
Lite probe is nonmagnetic and nonconducting, making it
compatible with MR technology (61). Although it is a
2 M. Nordsmark, Hypoxia Assessed by Oxygen Electrodes & 31P Mag-
netic Resonance Spectroscopy in Experimental Models and in Human
Tumors, p. 121. Ph.D. thesis, University of Aarhus, Aarhus, 1997.
promising tool for monitoring dynamic changes in oxygen
tension, OxyLite has been used only in experimental tu-
mors. Therefore, Eppendorf and OxyLite are not mu-
tually exclusive but rather are complementary.
A general advantage of oxygen electrodes is the direct
and rapid real-time measurements of absolute pO2 levels.
However, due to the invasive nature of the measurements,
these are feasible only in easily accessible tumors (46, 67).
In addition, the spatial resolution is low, and measurements
reflect the average oxygen tension over thousands of cells.
Therefore, it is not possible to distinguish necrosis from
severe hypoxia, which may bias measurements in tumors
with substantial amounts of necrosis.
Noninvasive Measurements of pO2
MR-based assays provide noninvasive, low-resolution
measurements of absolute pO2 values that are based on re-
corded spectra from paramagnetic agents. These paramag-
netic agents can be either endogenous, such as oxyhemo-
globin, or exogenous, such as charcoal emulsions or per-
fluorocarbons (68). When a contrast agent is not adminis-
tered, MR techniques are noninvasive. The available
techniques include the MR-based gradient recalled echo
(GRE) imaging, magnetic resonance imaging (MRI) (68),
electron paramagnetic resonance (EPR) oximetry (69, 70),
magnetic resonance spectroscopy (MRS) (71–73), and spin-
lattice relaxation of fluorinated MR agents (74).
Blood oxygen-dependent level (BOLD) imaging is an
MRI technique that is sensitive to the oxygenation status
of hemoglobin. The BOLD contrast results from the en-
dogenous change in paramagnetic deoxyhemoglobin, which
results in a variation in MRI signals and offers a nonin-
vasive tool to detect changes in tumor oxygenation without
the need for an exogenous contrast agent (75, 76). The
change in the oxygenation of rodent tumors upon carbogen
breathing illustrates that BOLD functional MRI is a poten-
tial and promising application for monitoring the response
of tissues to oxygenation-modifying treatments in the clin-
ical setting.
The EPR technique uses paramagnetic contrast agents
such as India ink or charcoal, which produce EPR spectra
reflecting the absolute oxygen tension (68, 69). The intra-
tumoral injection of the contrast agents is not trivial, and
EPR is a technically demanding method that is yet to be
validated in human tumors. However, it is a promising tech-
nique because one injection of a contrast agent is sufficient
for repeated measurements over a relatively long period.
Perhaps more important, it allows monitoring of changes in
oxygenation induced by, for instance, carbogen breathing
(68, 69, 77–79). The in vivo applications of EPR in exper-
imental tumors has made it clear that in vivo EPR has the
potential to be applied (1) for selection of treatments on an
individual basis based on pretreatment pO2 levels and (2)
for evaluation of early responses during oxygen-modifying
treatments.
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INDIRECT MEASUREMENTS OF OXYGEN TENSION:
ENDOGENOUS MARKERS OF HYPOXIA
Hypoxia is a potent modulator of gene expression, reg-
ulating 1–2% of the genome (56, 80), including genes for
growth factors that stimulate angiogenesis, cell proliferation
and metastasis (3, 4, 81–83). Genes and proteins involved
in the ‘‘hypoxia response’’ have received interest as poten-
tial endogenous markers of hypoxia, and several of these
proteins can be detected with immunohistochemistry.
Among the candidates are hypoxia inducible factor 1
(HIF1), carbonic anhydrase IX (CA-IX), osteopontin and
the facilitated glucose transporters 1 and 3 (GLUT1,
GLUT3). A large number of the genes involved in the
‘‘hypoxia response’’ may not be directly dependent on low
oxygen tensions; instead, expression could be induced by
tumor and microenvironmental factors such as differentia-
tion, availability of glucose and pH. For instance, hypoxic
cells often switch to anaerobic glycolysis, resulting in an
increased need for glucose, followed by up-regulation of
the GLUTs, eventually resulting in intracellular acidosis.
Subsequently the cells can respond to the low pH with ex-
pression of CA-IX. However, hypoxia-independent up-reg-
ulation of those genes cannot be excluded completely. This
complicates the interpretation of expression of endogenous
hypoxia markers and explains some of the conflicting re-
sults obtained in clinical studies. Nevertheless, an advan-
tage of endogenous hypoxia-related markers is that they can
be analyzed both in archival material and in prospective
clinical studies (51).
Hypoxia Inducible Factor 1
The transcription factor hypoxia inducible factor 1
(HIF1) plays an essential role in the adaptive response of
cells to hypoxia and is one of the key regulators of oxygen
homeostasis (84). Hydrolysis of its constitutively expressed
 subunit becomes inhibited under hypoxia, followed by
translocation to the nucleus. Heterodimerization of its  and
 subunits results in the active HIF1 protein that binds to
specific hypoxia-responsive elements in target genes, ulti-
mately activating transcription of these genes (85–87). Ac-
tive HIF1 mediates trans-activation of more than 60 genes
primarily involved in adaptation to hypoxia via glycolysis
and angiogenic signaling (87, 88). Among the better-known
HIF1-regulated gene products are vascular endothelial
growth factor (VEGF), erythropoietin (EPO), facilitated
glucose transporters 1 and 3 (GLUT1 and GLUT3) (86, 87,
89), and carbonic anhydrase IX (CA-IX) (90).
Since overexpression of HIF1A is common in solid tu-
mors and their metastases (91, 92), the gene product has
been evaluated as an endogenous hypoxia marker for sev-
eral tumor types. Studies of head and neck, bronchus and
brain tumors have shown an association between HIF1A
and failure of locoregional control and/or impaired disease-
free survival (93–96), although in some tumors the opposite
has been reported (96, 97). In addition to these inconsistent
results, a poor correlation of HIF1A with bioreductive hyp-
oxic markers such as pimonidazole and EF5 has been re-
ported (98–100). Furthermore, expression of HIF1A has
been reported in normally oxygenated tissues, which could
reflect glucose depletion, activation of HIF1A protein syn-
thesis or post-translational modification of the supporting
actors (80). Therefore, it is unlikely that HIF1A is specific
enough to function as a surrogate marker of hypoxia.
Carbonic Anhydrase IX
Carbonic anhydrases participate in a variety of biological
processes including pH regulation and respiration. The CA9
gene encoding the tumor-associated carbonic anhydrase IX
(CA-IX) is strongly up-regulated by hypoxia through HIF1
(90). Both the endogenous hypoxia-associated protein CA-
IX and the exogenous hypoxia marker pimonidazole can be
detected with immunohistochemistry in tumor sections.
Comparisons of CA-IX expression and pimonidazole bind-
ing by immunohistochemistry revealed similar patterns of
staining but lacked an absolute spatial co-localization (12,
101–104). The lack of an absolute spatial match between
pimonidazole and CA-IX suggests that it may become ex-
pressed at a different oxygen tension than the pO2 level at
which pimonidazole becomes reduced and binds to tumor
cells. In addition the slow induction and high stability of
CA-IX may explain some of the observed spatial differ-
ences between CA-IX expression compared to binding of
pimonidazole that was given shortly before tumor excision
(105–108). However, the relationship between CA-IX ex-
pression and prognosis is unclear since studies with and
without a significant association between these parameters
have been reported (12, 101, 104, 109–112). CA-IX re-
mains a promising endogenous marker of hypoxia since it
demonstrates staining patterns similar to bioreductive hyp-
oxia markers. Due to the kinetic profile of expression and
turnover, it may be regarded as an indicator of longer pe-
riods of predominantly diffusion-limited hypoxia.
Glucose Transporters
Facilitated glucose transporters (GLUTs) mediate cellular
glucose uptake and HIF1-mediated overexpression of glu-
cose transporters has been demonstrated in vitro (113).
Overexpression of the glucose transporters GLUT1 and
GLUT3 has been reported in a variety of human cancers
(114–119), and expression at distances further from the vas-
culature in perinecrotic areas suggests a relationship with
diffusion-limited hypoxia (120, 121). In carcinomas of the
uterine cervix, a significant correlation between GLUT1
and the exogenous hypoxia marker pimonidazole and be-
tween expression of GLUT1 and CA-IX was found. This
further supports a relationship between GLUT1 and hyp-
oxia (101). A weak correlation between GLUT1 and low
pO2 values detected by oxygen microelectrodes has been
reported in some but not all studies (120, 122). In addition,
conflicting results have been reported regarding GLUT1 as
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an indicator of prognosis (112, 117, 123). Therefore, it is
still unclear whether the glucose transporters are specific
enough to serve as endogenous hypoxia markers, and the
clinical value of these as a prognostic factor remains un-
clear.
Other Hypoxia-Related Proteins
Examples of other hypoxia-induced proteins that are un-
der investigation include IB kinase  (IKKB) (124), in-
volucrin (125), ostepontin (126), the epidermal growth fac-
tor (EGFR) (127), and the activating transcription factor 4
(ATF4) (128). However, it has not yet been proven whether
all these markers actually are up-regulated in vivo in hyp-
oxic tumor areas. It was demonstrated by Le et al. that
plasma osteopontin levels correlated with tumor hypoxia in
head and neck carcinomas as measured by Eppendorf mi-
croelectrodes (126). In addition, the DAHANCA 5 random-
ized trial showed that high osteopontin levels are associated
with poor outcome after radiotherapy. The poor outcome
could be improved by the use of the hypoxic cell radiosen-
sitizer nimorazole, and ostepontin could be used to identify
patients in whom treatment outcome could be improved by
hypoxia modification (129).
From the previous paragraphs it is clear that hypoxia-
regulated genes may also be influenced by other stressors
such as altered glucose and pH levels. Therefore, a proper
understanding of how the tumor microenvironment regu-
lates the expression of the endogenous hypoxia-related cell
markers is needed before these can be implemented in clin-
ical practice.
INDIRECT MEASUREMENTS OF OXYGEN TENSION:
EXOGENOUS HYPOXIC CELL MARKERS
Exogenous hypoxic cell markers are drugs, chemicals or
bacteria that, after administration, specifically accumulate
or become reduced within tumor cells under hypoxic con-
ditions.
Bacteria such as intravenously injected clostridia spores
have the ability to infiltrate and selectively colonize hyp-
oxic/necrotic regions of experimental tumors. The bacteria
can be genetically engineered to secrete therapeutic proteins
such as tumor necrosis factor  (130) or to express a re-
porter gene encoding, for instance, green fluorescent protein
(GFP) (131). Expression of the reporter gene provides in-
formation about the regions in which the bacteria accu-
mulate. Although reporter genes have been detected so far
only by imaging of small animals, it is a technique that can
become useful for monitoring delivery of therapeutic pro-
teins specifically targeting hypoxia cells.
One of the most sensitive methods for detecting hypoxia
is based on the observation that binding of 2-nitroimida-
zoles to cellular macromolecules occurs as a result of hyp-
oxia-dependent irreversible bioreduction by cellular nitro-
reductases at pO2 levels below approximately 10 mmHg
(132–134). Reduction and binding are integrated over the
time of drug exposure under hypoxic conditions and are
inhibited as a function of increasing oxygen concentration.
Several 2-nitroimidazoles can be used as hypoxia markers
and provide an inverse and indirect measurement of tumor
oxygenation. Some of the features of the most commonly
used 2-nitroimidazoles such as CCI-103F (135, 136), mi-
sonidazole (137–139), pimonidazole (132, 140) and EF5
(133, 141) are listed in Table 1. The latter three are ap-
proved for clinical use, and several methods are available
for detection of these markers. For instance, radioactively
labeled 2-nitroimidazoles can be detected by noninvasive
methods such as PET (142–144), MRS (71, 136) and
SPECT (144) or by autoradiography (138). Antibodies
raised against reduced and bound bioreductive markers can
be used for detection of hypoxic cells by means of three
different immunoassays; the enzyme-linked immunosorbent
assay (ELISA), flow cytometry (FCM) or immunohisto-
chemistry (IHC) of frozen or paraffin-embedded sections
(132, 133, 145–152). Table 2 shows an overview of the
assays that are suitable for detection of the most common
2-nitroimidazoles.
The ring structure and the nitro group are characteristic
features of all 2-nitroimidazoles, resulting in a similar ox-
ygen dependence of these drugs. However, the pharmaco-
kinetics and accumulation rates of these drugs differ be-
cause of unique properties of the side chains (Table 1). For
instance, at simultaneous administration or at short times
between injection, pimonidazole binds more extensively
(factor of 1.1–1.2) and more rapidly than CCI-103F (153–
155). Only 30 to 60 min is needed for distribution and
binding of pimonidazole for visualization by immunohis-
tochemistry compared to 2.5 h for CCI-103F (Table 2). The
reduction and binding of 2-nitroimidazoles are dependent
on oxygen, but the total amount of bound marker is also
affected by the accumulation rates in individual hypoxic
cells. In contrast to CCI-103F and EF5, the accumulation
rate of pimonidazole is dependent on pH. This can explain
the excess of pimonidazole binding that occurs mainly at
the vessel side of the diffusion-limited hypoxia, corre-
sponding to the area with an increasing gradient between
the intracellular and extracellular pH. There is reason to
assume that transient hypoxia will be preferentially detected
by pimonidazole since regions of fluctuating hypoxia are
likely to occur in the vicinity of the blood vessels.
The reduction and subsequent binding of the bioreduc-
tive markers require not only hypoxia but also intact nitro-
reductase enzymes (156). Therefore, these markers detect
only viable hypoxic cells and not necrotic cells. Differences
in nitroreductase activities among different cell types can
affect the intracellular concentration of reduced intermedi-
ates in hypoxic cells. This may contribute to discrepancies
in the quantitative analysis of hypoxia, especially in tumors
of different origins.
The reduced marker intermediates bind to cellular mac-
romolecules, with proteins being the major binding site
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TABLE 1
Some Features of the most Commonly Used 2-Nitroimidazoles
Marker name Chemical name
Solvent
P  octanol/
water
Dose
(species)
Plasma half-life
Rodent Dog Man
Clinically
approved
(regions of use)
T/Pa T/Bb
T/Mc Km (ppm)d Reference(s)
Misonidazole Ro
07-0582
1-(2-Hydroxy-3-
methoxypropyl)-
2-nitroimidazole
P  0.4 25–100 Me
(mice)
25–45 min 3.7 h
(i.v.) 5
h (oral
admin-
istra-
tion)
9.3 h Yes T/B  8 1000–3000 (138, 205–209)
NITP (A2-nitrom-
idazole)
7-(4-(2-nitroimida-
zol-1-yl)-butyl)-
theophylline
Peanut oil and
10% DMSO
156 mg kg1
(mice)
Stable during
the first 50
min, then 33
min
No 1400 ppm (151, 173,
210, 211)
CCI-103F (1-(2-hydroxy-3-
hexafluoroisopro-
poxy-propyl)-2-
nitroimidazole)
Peanut oil and
10% DMSO
or 0.9% NaCl
P  20
60–80 mg
kg1 (mice)
200 M
(rat) 40 mg
kg1 (dog)
40–90 min 7–8 h No T/P  0.8 (31, 136,
137, 147,
148, 212)
Pimonidazole (Ro
03-8799) Hy-
poxyprobeTM-1
(1-(2-nitro-1-imid-
azolyl)-3-N-pi-
peridino-2-propa-
nol)
0.9% NaCl P 
8.0
60–80 mg
kg1 (mice)
0.5 gm2,
max 1 g
(humans)
0.285 gm2
(dogs)
	30 min in
C3H mice
1.5 h 5–6 h Yes (Canada,
Europe,
USA)
T/P  3 1500 ppm
(0,15%)
(33, 133,
148, 177,
208, 213,
214)
EF5 [2-(2-nitro-1H-imi-
dazol-1-yl)-N-
(2,2,3,3,3-penta-
fluoropropyl)
acetamide]
0.9% NaCl (rat)
5% dextrose
in water with
2.5% alcohol
(man) P  4,
0–5.7
100 M (rat)
9–21 mg
kg1 (hu-
man)
150 min (rat) 12–14 h Yes (USA) (162, 208,
215)
F-MISO (18F-fluo-
ro-misonidazo-
le)
[18F]1-(2-nitro-1-
imidazolyl)-3-
fluoro-2-propanol
P  2.6 (also P
 0.43 have
been report-
ed)
	40 min 5–10 h Yes (Australia,
Europe,
USA)
T/B  2–3 (165)
a Tumor to plasma ratio.
b Tumor to blood ratio.
c Tumor to muscle ratio.
d May differ among tumor types for a certain marker.
e In both spheroids and plasma.
TABLE 2
Overview of Available Assays for the most Common 2-Nitroimidazoles
Marker name
Time to tumor excision
(minimum)
Stability of bound
marker/turnover
in tissue (tumor dependent) Detection method Reference(s)
Misonidazole 3 h before detection, injection
was repeated after 1 h and 2
h to maintain stable serum
levels over the 3 h (mice)
50–55 h in mice ARGa (138)
NITP (A2-nitroimidazole) 1–2 h in mice At least 28 h in anaplastic sar-
coma SaF in CBA/Ht Gy TO
mice
FCM,b IHCc (146, 210, 211)
CCI-103F 2 h in mice, 24 h in dogs Turnover: Mean  19 h in
dogs, Mean  8 h in mice
ELISA,d FCM, IHC (147)
Pimonidazole (Ro 03-
8799)
30–60 min in mice, 2 h in
patients
Up to 5 days ELISA, FCM, IHC (154)
EF5 3 h in mice, 24 h in patients At least 24 h IHC, PET, FCM (215, 216)
F-MISO (18F-fluoro-mi-
sonidazole)
PET
a Autoradiography.
b Flow cytometry.
c Immunohistochemistry.
d Enzyme-linked immunosorbent assay.
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(135), and after binding both the side chain and the ring
structure are retained (157–160). Upon binding, the 2-ni-
troimidazoles are fairly stable, but ultimately these will be-
come metabolized. Differences in the stability of reduced
and bound markers have been reported, indicating that in-
tracellular pimonidazole and 18F-misonidazole labeling are
more stable than CCI-103F labeling (146, 147). As an ex-
planation, it was suggested that the more hydrophobic side
chain of CCI-103F could be more prone to hydrolysis than
the hydrophilic side chain of pimonidazole (147). Poten-
tially, metabolism of bound adducts could be caused by
generalized protein turnover or cell division. However, oth-
er mechanisms are involved as well, since differences in
the turnover rates of reduced CCI-103F or pimonidazole
adducts have been observed among spontaneous canine tu-
mors (146, 147). In addition, turnover rates of hypoxic tu-
mor cells ranging from 16 to 54 h were observed among
different solid tumor lines (154). Therefore, the stability of
the bound marker in viable tumor tissue and the different
hypoxic cell turnover rates should be taken into account
when assessing hypoxia in tumors that are excised or bi-
opsied later than 16–24 h after injection of the hypoxia
markers.
As mentioned earlier, binding of 2-nitroimidazoles in
hypoxic cells is integrated over the exposure time, and the
labeled cells are often separated from the vasculature by
several layers of nonstained relatively normally oxygenated
cells. Therefore, it is assumed that 2-nitroimidazoles pre-
dominantly label diffusion-limited hypoxic cells (12, 25,
31, 33, 151, 161). However, repeated short episodes of hyp-
oxia may also be detected, which could explain the pres-
ence of pimonidazole binding near functional, perfused
blood vessels within 30–60 min after injection of the hyp-
oxia marker (152). Similarly, tumor cells labeled with both
a bioreductive hypoxia marker and a subsequently injected
S-phase marker (indicating replicative DNA synthesis) may
be transiently hypoxic (149, 150, 162), although such over-
lap could also be present in intermediate hypoxic areas.
Radiolabeling of 2-Nitroimidazoles
Most radiolabeled probes for the detection of hypoxia
have the radioactive element attached to bioreductive hyp-
oxia markers, which generally are 2-nitroimidazoles. The
ideal tracer should be highly specific and readily incorpo-
rated in hypoxic cells with a rapid washout. Subsequently,
the activity detected by PET or SPECT imaging should
reflect the uptake with a good signal-to-noise ratio. The
data on hypoxia can be assessed quantitatively in relation
to additional biological and pathological characteristics of
tissue such as metabolism, proliferation and blood flow
(163). The isotopes 123I (IAZA) and 99mTc (HL91) are avail-
able for SPECT, and 18F (F-miso, EF5, FAZA and FET-
NIM), 60Cu (Cu-ATSM) and 124I (IAZGP) are available for
PET (144). Although the clinical experience is limited for
some of the isotopes, all but FAZA and IAZGP have been
used in the clinic. So far, the most widely studied imaging
agent for hypoxia is 18F-MISO. Since the half-life of 18F is
as short as 110 min, the utility of 18F-MISO is limited main-
ly by its slow clearance kinetics, which delay specific im-
aging for up to 2–3 h after injection (164). Gro¨nroos et al.
reported that 18FAZA and 18FETNIM seem to be as feasible
as 18F-MISO. An advantage of 18FAZA and 18FETNIM is
the rapid clearance rates allowing shorter intervals between
injection and measurements compared to 18F-MISO (164,
165).
Several small clinical studies including advanced head
and neck cancer, lung cancer, cervical carcinomas and pros-
tate cancer indicate that detection of hypoxia with PET is
feasible. An advantage of 18F-MISO PET is that it can be
used repeatedly for tumor diagnosis and treatment follow-
up. In addition, it has been demonstrated for various tumor
sites that PET-based imaging of hypoxia has potential for
monitoring the effect of therapy and predicting tumor re-
sponse (166–169). Therefore, FMISO PET has a great po-
tential to become an important and useful tool for prog-
nostic and predictive assays, especially in patients where
surgery is not indicated, and repeated scans may provide a
tool to revise treatment strategies.
Analysis of PET in relation to CT can detect some degree
of spatial heterogeneity of hypoxia at the macroscopic level
(144, 170). Nevertheless, it should be kept in mind that
each voxel (5 mm) in a clinical PET image integrates the
oxygenation status of several tumor cords. For instance,
Wijffels et al. showed that in advanced HNSCC the vas-
cular density was 41 to 305 vessels/mm2 (33). Therefore, it
can be assumed that 1 mm3 contains approximately 260 to
5360 vessels. With a PET voxel size of 5 mm3, the average
number of tumor vessels in each voxel is immense. A dis-
advantage of PET is that it does not allow discrimination
between microregional necrosis and viable nonhypoxic
(MISO negative) tumor cells. Another disadvantage of PET
imaging of 2-nitroimidazoles is the need to use short-lived
isotopes such as 123I and 18F, requiring a cyclotron either on
site or nearby (171).
In experimental studies, immunohistochemistry of CCI-
103F yielded comparable patterns of binding compared to
autoradiography of misonidazole in both spheroids and tu-
mor sections (135). Also, the patterns of pimonidazole de-
tected with immunohistochemistry were comparable to au-
toradiography of misonidazole (140). These studies indicate
that those markers have similar oxygen dependences.
Immunodetection of 2-Nitroimidazoles
Reduced and bound 2-nitroimidazoles are stable in tumor
cells during normal histological processing, and detection
with antibodies is a relatively rapid method. CCI-103F was
the first (135) and NITP (172) was the second hypoxia
marker that could be detected by means of antibodies. A
disadvantage of these substances was the poor water solu-
bility. In mice, a vehicle of DMSO and peanut oil was
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necessary for intraperitoneal administration, and these
markers were never approved for clinical use (172). This
led to the development of antibodies against more suitable
hypoxia markers such as EF5 (173) and pimonidazole
(132). Unfortunately, attempts to raise antibodies against
reduction products of misonidazole, the most widely used
imaging agent, resulted in antibodies with relatively weak
specificity that were unsuitable for general use (171).
Enzyme-Linked Immunosorbent Assay
The enzyme-linked immunosorbent assay (ELISA) is an
easy and rapid method for quantitative analysis of the con-
centration of bound hypoxia marker in a large number of
tumor cells. Since cell lysates are used for the measure-
ments, the assay does not give information about the num-
ber of labeled cells or their spatial distribution. In addition,
with ELISA no discrimination can be made between normal
and tumor cells. Moreover, this assay cannot distinguish
between a large number of cells with low to intermediate
binding and a low number of cells with high-intensity bind-
ing of the hypoxia markers, since each of these situations
may result in the same antigen concentration. All quanti-
tative measurements of the amounts of reduced and bound
bioreductive markers may be affected by intertumoral dif-
ferences in reductase levels. However, due to the use of
total cell lysates, ELISA is more sensitive to intertumoral
differences in reductase activities compared to assays that
detect hypoxia marker labeling as function of labeled tumor
surface fraction or of the fraction labeled intact tumor cells.
An advantage of ELISA is that it is suitable for rapid
screening of the presence or absence of tumor cell hypoxia
in large series (146, 147, 174).
Flow Cytometry
Flow cytometry allows rapid analysis of a large number
of tumor cells in single cell suspension. Using triple stain-
ing, hypoxia can be compared to other tumor cell markers
on an individual cell basis (148, 150). In addition, cell sort-
ing of hypoxic cells, based on the fluorescence intensity of
the perfusion marker Hoechst 33342, provides information
about the distribution of hypoxic cells as a function of the
distance from the perfused (functional) blood vessels (148,
175). Simultaneous analysis of NITP, BrdUrd and total
DNA content analyzed with flow cytometry provided the
first evidence of a small hypoxic cell population in active
cell cycle (150). Analysis of bioreductive hypoxic cell
markers in relation to markers of cell proliferation in tumor
sections confirmed this observation (149), but proliferating
hypoxic cells may not be present in all tumors (148).
Tumor Sections
Immunostaining of tumor sections for 2-nitroimidazoles
allows microscopic image analysis of the spatial distribu-
tion of individual hypoxic cells relative to microenviron-
mental parameters such as vasculature, proliferation and en-
dogenous hypoxia-related markers (12, 25, 33, 101, 102,
149, 176). This provides in vivo-ex vivo information of the
physiology of hypoxic cells in relation to other important
cellular processes (Fig. 1). Immunohistochemical analysis
of exogenous hypoxia markers has been applied in both
experimental and clinical studies. Also, direct comparisons
can be made between primary tumors and the correspond-
ing xenografts such as illustrated by a comparison of the
endogenous proliferation marker (Ki67) between patient bi-
opsies and the corresponding xenografts (177). In experi-
mental tumor models, intratumoral changes in hypoxia can
be analyzed by means of consecutive injections of two dif-
ferent hypoxia markers (Fig. 2). It is also possible to com-
bine microscopic analysis of 2-nitroimidazoles with other
imaging modalities such as PET.
In tumor sections, hypoxia can be quantified by estimat-
ing the fractions of stained cells by visual semi-quantitative
scoring or digital image analysis (12, 25, 100, 151, 178).
Hypoxia can also be quantified as a function of the fluo-
rescence intensity of bound markers calibrated against in
vitro binding of the bioredcutive markers in hypoxic cells
at a known pO2 (67). In tumor sections from patients with
head and neck carcinomas of the same stage and anatomical
origin, three different spatial patterns of hypoxic tumor
cells were observed: (1) patchy hypoxia, (2) band-like hyp-
oxia at large distances from the vasculature, and (3) tumors
with hypoxia near the tumor vasculature (33). These have
also been observed in human tumors of different origin and
in canine tumors as well as in xenografts of human head
and neck carcinomas grown in nude mice (25, 31, 149).
The clinical relevance of the hypoxia patterns is not yet
known, but they may be related to hypoxia tolerance, hyp-
oxic cell turnover rate and cell loss.
APPLICATIONS OF IMMUNOHISTOCHEMICAL
ASSAYS
Predictive Value of Pimonidazole
As mentioned earlier, tumor cell hypoxia contributes to
resistance to radiation. In addition, the efficacy of oxygen-
modifying treatments aimed at improving tumor oxygena-
tion may vary among individual patients. Therefore, de-
velopment of reproducible and rapid predictive assays may
improve the ability to select patients that would benefit
from specific oxygen-modifying treatments. In a recent
clinical study of head and neck tumors, high pimonidazole
binding correlated with poor treatment outcome (12). This
has also been observed with EF5 in soft tissue sarcomas
(49). In the head and neck study, the benefit of hypoxia-
based intervention with ARCON [accelerated radiotherapy
combined with carbogen (95% O2 and 5% CO2) and nico-
tinamide] was confirmed since the predictive power of pi-
monidazole binding disappeared in the ARCON-treated
group (12). Although these results are promising, the clin-
ical experience with exogenous hypoxia markers is limited
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FIG. 1. Photomicrographs of patient biopsies of human head and neck squamous cell carcinomas. Panel A: The SCCNij53 tumor at 100
 magni-
fication showing hypoxia (green, pimonidazole) in relation to vasculature (red, pal-E) and proliferation (purple, IdUrd). Panel B: A detail of the
SCCNij70 tumor at 200
 magnification showing a hypoxic area (green) enclosing apoptotic cells stained with the TUNEL assay (red). Necrosis (N)
and keratin (K); scale bar is 100 m.
to studies with small numbers of patients. The possibility
to use pimonidazole as a predictive marker will be evalu-
ated in an ongoing randomized phase III ARCON trial
(179), in which the most promising endogenous markers of
hypoxia and proliferation will also be validated against pi-
monidazole binding.
Novel assays such as assessment of hypoxia with the
bioreductive markers pimonidazole and EF-5 have been
compared to the Eppendorf electrode since the latter has
been regarded as the gold standard for clinical studies. One
study showed a correlation between the hypoxic fraction
determined by pimonidazole binding and pO2 (180), while
others did not report significant correlations (181–183). The
poor spatial resolution in the electrode data compared to
the detailed microregional information obtained by the hyp-
oxia markers can explain some of the discrepancies be-
tween these assays (182, 183). In contrast, the hypoxic frac-
tion of pimonidazole correlated better with the radiobiolog-
ical hypoxic fraction in individual cells assessed by the
comet assay than with Eppendorf measurements. This
demonstrates the limitations of the Eppendorf method at
the microregional and cellular levels (50). The hypoxic
fractions determined using pimonidazole or EF5 measured
in tumor biopsies predicted outcome for patients treated
with radiotherapy (12, 49) and may therefore become a new
gold standard for assays detecting hypoxia at the cellular
level.
Dynamics of Hypoxia: Consecutive Injection of Hypoxia
Markers
In tumor sections stained for hypoxia markers, treatment-
induced changes in hypoxia can be visualized in relation to
the vascular architecture and other cellular markers. In the
xenografted human squamous cell carcinoma SCCNij3, car-
bogen breathing resulted in a decrease of hypoxia, detected
with NITP, and of proliferation, detected with BrdUrd, com-
pared to the air-breathing control animals. Thus a simulta-
neous improvement in oxygenation (reduced hypoxia) and
decrease in tumor cell proliferation were observed and
quantified (184). This technique has also been applied in
human tumors grown as xenografts to study for instance
the effects of the antiangiogenic compound SU-5416 (185)
or radiation (151) on hypoxia in relation to vasculature and
blood perfusion.
A pioneering study using two consecutively injected per-
fusion markers, Hoechst 33342 (175, 186) and DiOC7(3)
(187, 188), provided direct evidence of transient changes
in blood perfusion in vivo (38), suggesting the presence of
temporal fluctuations in tumor oxygenation. It inspired de-
velopment of double hypoxia marker assays with consec-
utive injections of two different 2-nitroimidazoles for anal-
ysis of changes in hypoxia in individual experimental tu-
mors (153, 154, 164, 189–192). Since each tumor serves
as its own control, these assays eliminate the effect of in-
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FIG. 2. Panel A: Composite binary image of a human mucoepidermoid carcinoma MEC82 that was grown as a xenograft in nude mice, with
vasculature (white), perfusion marker Hoechst 33342 (blue), first hypoxia marker (pimonidazole, green), and second hypoxia marker (CCI-103F, red).
Spatial co-localization of both markers (red  green) appears as yellow. At an injection interval of 2 h, most of the hypoxic cells were labeled by
both the first and second hypoxia marker. Transient hypoxia is illustrated as an area that was not hypoxic at the time of the injection of the first marker
but had become hypoxic at the time of the second hypoxia marker injection (red only, star in panel A). Panel B: A detail of the area with transient
hypoxia. The brightness of the colors reflects the differences in staining intensities in the original grayscale scans. Scale bar  500 m.
tertumor heterogeneities in hypoxic fractions within the
same tumor line and histology.
The first double hypoxia marker study used -D-iodin-
ated azomycin galactoside (IAZG) labeled with iodine-125
and -D-iodinated azomycin xylopyramoside (IAZXP) la-
beled with iodine-131. The hypoxia markers were detected
with SPECT. Upon co-injection in rodent tumors, the intra-
tumoral variation of the two markers was only 4%. In con-
trast, at an injection interval of 2.5 to 3 h, a mismatch that
was larger than 8% was found in 8 of 18 tumors. This was
interpreted as evidence for significant amounts of transient
hypoxia (190). With this assay, significant changes in la-
beling between the first and second marker were found
upon treatment with carbogen and nicotinamide. An advan-
tage of that assay was that two almost identical hypoxia
markers were used, but a disadvantage was the poor spatial
resolution. In a study of human tumors grown as xeno-
grafts, sequential administration of multiple doses of pi-
monidazole resulted in significantly larger hypoxic frac-
tions compared to a single administration of CCI-103F. The
hypoxia markers were detected by means of flow cytome-
try, and the difference between pimonidazole and CCI-
103F was interpreted as the amount of hypoxic cells ex-
posed to intermittent periods of hypoxia. The proportion of
tumors with transient hypoxia was 20% in SiHa tumors
compared to 8% in WiDr tumors, indicating that large het-
erogeneities exist between solid tumors of different histol-
ogy and origin (189). The presence of transient hypoxia can
also be detected by means of immunohistochemistry upon
sequential injection of two hypoxia markers. Presumably,
the tumor cells that are labeled with only the first or only
the second hypoxia marker in the human head and neck
tumor line grown as xenograft (Fig. 2) experienced tran-
sient changes in hypoxia during the 2-h interval between
the injections of the hypoxia markers.
Upon consecutive injection of the two hypoxia markers,
microscopic image analysis of tumor sections can be used
for analysis of both spatial and temporal changes in hypoxia
in relation to the vascular architecture and other cellular
markers (153, 154, 191). Examples of applications using
this technique include changes in hypoxia during carbogen
breathing (153, 191), after hydralazine treatment (153), and
after irradiation (192). In addition, the dynamics of hypoxic
cells in untreated tumors have been analyzed with this tech-
nique (154). By varying the sequence of injection of pi-
monidazole and CCI-103F, the pharmacokinetic differences
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FIG. 3. Composite binary images of consecutive tumor cross sections from the human head and neck squamous cell carcinoma SCCNij3, grown as
a xenograft in nude mice, with perfusion marker Hoechst 33342 (blue), vascular endothelium (9F1, red), first hypoxia marker CCI-103F (panel A) and
second hypoxia marker pimonidazole (panel B) (both green). There was a good spatial match between the two hypoxia markers in air-breathing control
animals. CCI-103F was injected during air breathing (panel A) and acts as reference marker, and pimonidazole was injected during carbogen breathing.
The decrease in hypoxia during carbogen breathing was detected with pimonidazole (panel B, arrows) compared to pretreatment levels of hypoxia
detected with CCI-103F (panel A). Scale bar is 1 mm. For details, see ref. (154).
between these markers can be exploited. For instance, using
pimonidazole as the second marker, it is possible to detect
rapid changes in hypoxia since the time between injection
and tumor resection can be as short as 30 min (153). In
contrast, when studying the dynamics of hypoxia over lon-
ger times, pimonidazole is preferred as the first marker due
to its high intracellular stability. With consecutive injection
of the clinically approved markers pimonidazole and EF5,
the double hypoxia marker assay can be developed to mon-
itor effects of different oxygen-modifying treatments in in-
dividual patients. This approach should be explored.
Effects of Oxygen-Modifying Treatments
Figure 3 shows an example of the double hypoxia marker
assay applied in a study on the effect of carbogen breathing
in relation to vasculature and blood perfusion in the human
squamous cell carcinoma xenograft line SCCNij3. Carbo-
gen breathing resulted in a decrease in hypoxia since there
was significantly lower binding of the second hypoxia
marker pimonidazole (right) compared to the reference
marker CCI-103F (left). The decrease was most pro-
nounced in hypoxic areas near perfused vessels, but in larg-
er perinecrotic areas, there was an evident but not complete
decrease in hypoxia (153). These cells were situated beyond
the diffusion gradient of oxygen even after hyperoxygena-
tion and were probably also subject to reduced concentra-
tions of nutrients, yet these cells were exposed to the hyp-
oxia markers and were still metabolically able to reduce
and bind the hypoxia markers. It is likely that these hypoxic
cells would die within a short time in unperturbed tumors,
but it is a cell population that could become important upon
reoxygenation during radiotherapy.
Hypoxic Cell Turnover Rate
Consecutive injections of the two hypoxia markers pi-
monidazole and CCI-103F with different intervals have
been performed in the murine C38 colon adenocarcinoma
tumor line (Fig. 4). Pimonidazole was given at variable
times (2–120 h) before CCI-103F. The latter was always
given 2.5 h before the animals were killed as reference level
of hypoxia at time of analysis. At short times, there was a
good spatial co-localization of the two markers. In contrast,
at longer times, the first hypoxia marker decreased. This
resulted in the appearance of a few cell layers labeled only
with the second hypoxia marker at the vessel side of areas
that were stained for both hypoxia markers. Cell debris in
necrotic areas that was labeled with the first hypoxia marker
indicated that the decrease in the first hypoxia marker was
caused by death of initially hypoxic cells (154). Those cells
were viable and hypoxic at the time of the first marker
injection, which resulted in binding, but in the interval be-
tween binding and tumor excision, those cells had died and
were subject to fragmentation. By calculating a normalized
ratio of the hypoxic fractions for the first over the second
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FIG. 4. The murine colon adenocarcinoma C38 tumor with vasculature (9F1, white), the first hypoxia marker pimonidazole (green), and the second
hypoxia marker CCI-103F (red). Overlap of the two hypoxic markers is yellow (red  green). Panel A: An excellent spatial match of the first and
second hypoxia marker at a short injection interval in a tumor from an untreated animal was observed. Panel B: At 28 h after injection of the first
hypoxia marker in an untreated animal, a red margin of the second hypoxia marker only (red) had appeared at the vessel side of tumor cells labeled
with both hypoxia markers. The difference in labeled areas between the first and second hypoxia marker reflects hypoxic cell turnover. Panel C: At
28 h after treatment with a single dose of X rays (20 Gy), the number of remaining cells that were labeled with the first marker (hypoxic at time of
irradiation) was larger than in panel B, indicating that the turnover rate of initially hypoxic cells decreased after irradiation. In addition, after irradiation
the oxygenation status increased since the second hypoxia marker CCI-103F (red) had decreased compared to the untreated examples (panels A and
B). Scale bar  1 mm.
hypoxia marker for a number of times, the half-life of the
turnover rate of hypoxic tumor cells was calculated. Among
the three different tumor lines that were analyzed in that
study, the hypoxic cell turnover rate differed by a factor of
three (154). The observed tumor cell line dependence is sup-
ported by other studies, which indicate that the life span of
hypoxic cells may range from a few hours to several days
(147, 193–198). The tumor cell line-dependent differences
in hypoxic cell turnover rate and tumor growth illustrate that
it is impossible to extrapolate data from a single tumor mod-
el to a diverse population of primary tumors. Furthermore,
the data indicate that the optimal timing of combined mo-
dality treatment schedules can be dependent on the tumor,
which should be taken into consideration in the design and
interpretation of experimental and clinical studies.
Dynamics of Hypoxic Cells after Irradiation
The double hypoxia marker assay was also used to study
the effect of radiation (20 Gy, single dose) on hypoxia,
proliferation and cell death (apoptosis) in the murine C38
tumor line (192). The spatial distribution of the two hyp-
oxia markers at short injection intervals was used as control
(Fig. 4A). The first hypoxia marker, pimonidazole, was giv-
en 1 h before treatment to label cells that were hypoxic at
the time of irradiation. The second hypoxia marker (CCI-
103F, red) was given at variable times after irradiation and
always at a fixed time, 2 h, before tumor excision. Most
tumor cells that were hypoxic at time of irradiation had an
improved oxygenation status at 8 h after treatment that re-
mained unchanged over the subsequent 20 h (Fig. 4C). In
addition, it was concluded that radiation caused a signifi-
cant decrease in the turnover rate of cells that were hypoxic
at the time of irradiation since a larger number of initially
hypoxic cells were present in irradiated tumors (Fig. 4C)
compared to the untreated tumors (Fig. 4B) (192). This is
in agreement with other studies showing that radiation-in-
duced temporary improvements of tumor oxygenation can
occur within hours and may last for a few days (151, 199–
203). Therefore, in many tumors, a radiation-induced im-
provement in oxygenation status will affect the efficacy of
the subsequent dose in a fractionated treatment schedule. It
is likely that the kinetics of reoxygenation is affected by
intrinsic differences in the turnover rate of hypoxic cells,
which may contribute to intertumor heterogeneities in ra-
diation response. In the murine C38 tumor line, the im-
proved oxygenation status after irradiation was interpreted
as a decrease in the net cellular respiration resulting from
a lower number of proliferating cells and decreased cell
density as shown by proliferation and apoptosis markers in
combination with the double hypoxia marker assay (192).
Although the study was limited to one tumor line, it illus-
trates the possibility to study multiple parameters in one
biopsy or tumor after injection of two hypoxia markers, one
proliferation marker and visualization of apoptosis. This as-
say can also provide information about temporal and spatial
changes for different cellular processes and allows inter-
pretation of treatment effects in relation to specific tumor
cell populations (192).
Development of this assay for clinical use would provide
a means of dynamic measurements of hypoxia during ox-
ygen-modifying treatments such as carbogen breathing and
could enable selection of responding and nonresponding
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patients. For the nonresponders, a reduction of unnecessary
overtreatment would result in decreased side effects for
these patients, allowing selection of another treatment mo-
dality that might be more appropriate, for example specif-
ically targeting hypoxic cells, for instance with tirapaza-
mine. The double hypoxia marker assay provides a means
to study the effect of novel treatments on the dynamics of
hypoxic tumor cells in experimental tumors. If performed
on a panel of experimental tumor lines with large differ-
ences in the dynamics of hypoxia, this technique can pro-
vide a basis for further development of predictive assays
and improved design of combined-modality treatments.
SUMMARY
There is convincing evidence of the clinical importance
of tumor hypoxia, but detection of hypoxia is still limited
in routine clinical practice. Many investigators have re-
garded the Eppendorf electrode, which is limited to easily
accessible tumors and a few research centers, as a gold
standard. However, assays for routine clinical use need to
be user friendly and preferable commercially available at
reasonable cost. PET- or MR-based noninvasive imaging
techniques are potential candidates for routine use, although
the poor spatial resolution is a limitation of these methods.
These techniques still need to be validated against knowl-
edge of hypoxia at the microscopic level. Bioreductive
drugs that label metabolically active hypoxic cells such as
pimonidazole and EF5 are appropriate for this purpose, and
both pimonidazole and EF5 have potential value for pre-
diction of the treatment outcome. Bioreductive hypoxia
markers can be detected with several techniques such as
PET and autoradiography and in tumor sections by micro-
scopic imaging techniques. With the latter, hypoxia can be
studied in relation to other microenvironmental parameters
such as vasculature and proliferation at high spatial reso-
lution. Sequential injection of two different exogenous hyp-
oxia markers in experimental tumors has demonstrated that
in tumor sections, spatial and temporal changes in hypoxia
can be analyzed in relation to other tumor microenviron-
mental parameters. This technique can be used for analysis
of changes in hypoxia in both treated and untreated tumors
and can be applied clinically by means of sequential ad-
ministration of pimonidazole and EF5.
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